Scientists from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, have developed a novel ultrasound-driven therapy that activates dormant cancer drugs directly inside tumors. By combining low-intensity ultrasound with specially designed nanoparticles, the team achieved a 99% tumor suppression rate and 66.7% cure rate in mice. This non-invasive approach minimizes side effects and could revolutionize targeted cancer treatment.

For both men and women without a Bachelor’s degree (BA), a new study in JAMA Health Forum found that mortality between 2011-2023 was markedly higher than would have been expected had death rates from 2006-2010 continued. Among 564,855 excess deaths in 2023 alone, 481,211 occurred among people without a BA—a 26 percent increase in mortality among this population, compared to pre-2010 trends. In contrast, mortality only increased by eight percent among people who received a BA. 

Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program and the Paula J. O'Keeffe Endowed Chair of the Mass General Cancer Center, is senior author and Stefanie Bailey, PhD, Hana Takei, and Giulia Escobar, PhD of the Krantz Family Center for Cancer Research at Massachusetts General Hospital are co-lead authors of a paper published in Science Translational Medicine, “IFN-g-resistant CD28 CAR-T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models.”

(WASHINGTON, June 13, 2025) – Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare T-cell lymphoma, compared with similar women without these genetic mutations, according to a study published today in Blood Advances.